KURAKura Oncology, Inc.Finished
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
HNSCC
16Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Aug 2025, none posted yet
Counts until it's fixed
- +6.4
2 insiders sold shares within a month
Since Sep 28, 2026 · was worth 10, fading over time
Worry score16
Score over time
- Stage
- Phase 1/2
- Patients
- 45 (final count)
- Started
- Dec 7, 2021
- Main results expected
- Aug 29, 2025
- Fully finished
- Aug 29, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose-limiting toxicity (DLT)
Measured over: First 28 days (1 cycle) of combination therapy
Descriptive statistics of Adverse Events (AEs)
Measured over: From Cycle 1 Day 1 until 30 days after last trial intervention dose or 30 days after trial completion, whichever comes first, assessed up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-08-29, no fading
- insider_selling_cluster: base 10, now 6.4, since 2026-09-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04997902 · record last updated 2026-09-08 · checked 2026-11-09 15:47 UTC